These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 10211790

  • 1. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
    Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T, Schmidt-Wolf I.
    Hybridoma; 1999 Feb; 18(1):63-8. PubMed ID: 10211790
    [Abstract] [Full Text] [Related]

  • 2. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf I.
    Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A, Cameron RB, Rosenberg SA.
    J Immunol; 1990 Jun 01; 144(11):4463-71. PubMed ID: 2111349
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    Lung Cancer; 2009 Jan 01; 63(1):23-31. PubMed ID: 18524412
    [Abstract] [Full Text] [Related]

  • 8. The combination of interleukin-2 and interferon alpha effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29.
    Bungard S, Flieger D, Schweitzer S, Sauerbruch T, Spengler U.
    Cancer Immunol Immunother; 1998 Jun 01; 46(4):213-20. PubMed ID: 9671144
    [Abstract] [Full Text] [Related]

  • 9. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ, Scott AM.
    Cancer Immun; 2002 Oct 07; 2():13. PubMed ID: 12747758
    [Abstract] [Full Text] [Related]

  • 10. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).
    Masucci G, Lindemalm C, Frödin JE, Hagström B, Mellstedt H.
    Hybridoma; 1988 Oct 07; 7(5):429-40. PubMed ID: 3198133
    [Abstract] [Full Text] [Related]

  • 11. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
    Morgan AC, Sullivan W, Graves S, Woodhouse CS.
    Cancer Res; 1989 May 15; 49(10):2773-6. PubMed ID: 2785437
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
    Masucci G, Wersäll P, Nielsen J, Nielsen HK, Wigzell H, Mellstedt H.
    Hybridoma; 1989 Oct 15; 8(5):507-16. PubMed ID: 2807310
    [Abstract] [Full Text] [Related]

  • 14. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF.
    Breast Cancer Res Treat; 1999 Feb 15; 53(3):199-207. PubMed ID: 10369066
    [Abstract] [Full Text] [Related]

  • 15. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM.
    Cancer Immunol Immunother; 2002 May 15; 51(3):171-7. PubMed ID: 11941456
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.
    Pullyblank AM, Guillou PJ, Monson JR.
    Br J Cancer; 1995 Sep 15; 72(3):601-6. PubMed ID: 7669568
    [Abstract] [Full Text] [Related]

  • 17. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ.
    MAbs; 2015 Sep 15; 7(3):494-504. PubMed ID: 25933349
    [Abstract] [Full Text] [Related]

  • 18. Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (PPD), and anti-IL-10 antibody.
    Baj-Krzyworzeka M, Baran J, Szatanek R, Stankiewicz D, Siedlar M, Zembala M.
    Cancer Immun; 2004 Aug 25; 4():8. PubMed ID: 15327279
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor and interferon-gamma augment anticolon antibody- dependent cellular cytotoxicity in ulcerative colitis.
    Watanabe N, Maeda M, Okamoto T, Sasaki H, Tsuji N, Akiyama S, Kobayashi D, Sato T, Yamauchi N, Niitsu Y.
    Immunopharmacol Immunotoxicol; 1996 Feb 25; 18(1):15-26. PubMed ID: 8683036
    [Abstract] [Full Text] [Related]

  • 20. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
    Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Riethmuller G, Daddona PE.
    Cancer Res; 1988 Nov 15; 48(22):6303-8. PubMed ID: 2460221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.